When facing cancer, patients and doctors want every possible clue about what lies ahead. A new analysis of existing research suggests a simple, affordable blood test might offer one such clue. The test looks at the ratio of two common substances measured in blood—creatinine and cystatin C—which are markers of kidney function. A low ratio, called CCR, was linked to shorter survival times in people with cancer.
The researchers pooled data from 12 different studies involving 4,439 individuals with cancer. They found that people with a low CCR had a higher risk of dying from any cause during the study period. The strength of this link was notable, with a 71% higher risk for overall survival and a 51% higher risk for the cancer progressing or the patient dying. However, the analysis didn't report the actual number of people who died or how long the studies followed patients.
It's crucial to understand what this finding means—and what it doesn't. This is a correlation, meaning the two things—a low CCR and shorter survival—were observed together. It does not prove that a low CCR causes worse outcomes. The analysis combined different types of observational studies, which can't establish cause and effect. We also don't know which specific types of cancer were involved or if there were other factors at play. The researchers call CCR a 'promising' biomarker, but more research is needed to see if it's truly useful for guiding care.
